|
1
|
Rothwell PM, Fowkes FG, Belch JF, Ogawa H,
Warlow CP and Meade TW: Effect of daily aspirin on long-term risk
of death due to cancer: Analysis of individual patient data from
randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: A study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mills EJ, Wu P, Alberton M, Kanters S,
Lanas A and Lester R: Low-dose aspirin and cancer mortality: A
meta-analysis of randomized trials. Am J Med. 125:560–567. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Algra AM and Rothwell PM: Effects of
regular aspirin on long-term cancer incidence and metastasis: A
systematic comparison of evidence from observational studies versus
randomised trials. Lancet Oncol. 13:518–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lichtenberger LM, Phan T, Fang D and Dial
EJ: Chemoprevention with phosphatidylcholine non-steroidal
anti-inflammatory drugs in vivo and in vitro. Oncol
Lett. 15:6688–6694. 2018.PubMed/NCBI
|
|
6
|
Huang Y, Lichtenberger LM, Taylor M,
Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu
W, Previs RA, et al: Antitumor and antiangiogenic effects of
aspirin-PC in ovarian cancer. Mol Cancer Ther. 15:2894–2904. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dial E, Doyen JR and Lichtenberger LM:
Phosphatidylcholine- associated nonsteroidal anti-inflammatory
drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer
cells in vitro. Cancer Chemother Pharmacol. 57:295–300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cryer B, Bhatt DL, Lanza FL, Dong JF,
Lichtenberger LM and Marathi UK: Low-dose aspirin-induced
ulceration is attenuated by Aspirin-Phosphatidylcholine: A
randomized clinical trial. Am J Gastroenterol. 106:272–277. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takkouche B, Regueira-Méndez C and Etminan
M: Breast cancer and use of nonsteroidal anti-inflammatory drugs: A
meta-analysis. J Natl Cancer Inst. 100:1439–1447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holmes MD, Chen WY, Li L, Hertzmark E,
Spiegelman D and Hankinson SE: Aspirin intake and survival after
breast cancer. J Clin Oncol. 28:1467–1472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fraser DM, Sullivan FM, Thompson AM and
Mccowan C: Aspirin use and survival after the diagnosis of breast
cancer: A population-based cohort study. Br J Cancer. 111:623–627.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Egan KM, Stampfer MJ, Giovannucci E,
Rosner BA and Colditz GA: Prospective study of regular aspirin use
and the risk of breast cancer. J Natl Cancer Inst. 88:988–993.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Menamin ÚM, Cardwell C, Hughes C and
Murray L: Low-dose aspirin use and survival in breast cancer
patients: A nationwide cohort study. Cancer Epidemiol. 48:1582017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Add-aspirin, . A trial assessing the
effects of aspirin on disease recurrence and survival after primary
therapy in common non metastatic solid tumours status: Recruiting.
First posted 2017. ClinicalTrials.gov identifier: NCT02804815.
https://clinicaltrials.gov/ct2/show/NCT02804815
|
|
15
|
Aspirin in preventing recurrence of cancer
in patients with HER2 negative stage II–III breast cancer after
chemotherapy, surgery and/or radiation therapy status, .
Recruiting. First posted 2016. ClinicalTrials.gov identifier:
NCT02927249. https://clinicaltrials.gov/ct2/show/NCT02927249
|
|
16
|
Low dose chemotherapy with aspirin in
patients with breast cancer after neoadjuvant chemotherapy status,
. Unknown status. First posted 2012. ClinicalTrials.gov identifier:
NCT01612247. https://clinicaltrials.gov/ct2/show/NCT01612247
|
|
17
|
Kennedy BM and Harris RE: Cyclooxygenase
and lipoxygenase gene expression in the inflammogenesis of breast
cancer. Inflammopharmacology. 2018.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu XH and Rose DP: Differential
expression and regulation of cyclooxygenase-1 and −2 in two human
breast cancer cell lines. Cancer Res. 56:5125–5127. 1996.PubMed/NCBI
|
|
19
|
Clarke CA, Canchola AJ, Moy LM, Neuhausen
SL, Chung NT, Lacey JV Jr and Bernstein L: Regular and low-dose
aspirin, other non-steroidal anti-inflammatory medications and
prospective risk of HER-2 defined breast cancer: The california
teachers study. Breast Cancer Res. 19:522017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marshall SF, Bernstein L, Anton-Culver H,
Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie
DM, Reynolds P, et al: Nonsteroidal anti-inflammatory drug use and
breast cancer risk by stage and hormone receptor status. J Natl
Cancer Inst. 97:805–812. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Smith-Warner SA, Collins LC,
Rosner B, Willett WC and Hankinson SE: Use of aspirin, other
nonsteroidal anti-inflammatory drugs, and acetaminophen and
postmenopausal breast cancer incidence. J Clin Oncol. 30:3468–3477.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amaral MEA, Nery LR, Leite CE, de Azevedo
Junior WF and Campos MM: Pre-clinical effects of metformin and
aspirin on the cell lines of different breast cancer subtypes.
Invest New Drugs. 36:782–796. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta R, Fang D and Lichtenberger LM:
Mo1985-evaluation of the inhibitory efficacy and potency of
PC-NSAIDs on pancreatic cancer cells in culture. Gastroenterol. 154
(Suppl 6):S–872. 2018. View Article : Google Scholar
|
|
24
|
Lichtenberger LM, Fang D, Bick RJ,
Poindexter BJ, Phan T, Bergeron AL, Pradhan S, Dial EJ and Vijayan
KV: Unlocking aspirin's chemopreventive activity: Role of
irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prev Res
(Phila). 10:142–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lichtenberger LM: Purified
phospholipid-non-steroidal anti-inflammatory drug associated
compositions and methods for preparing and using same. US patent
8,802,656 B2. Filed October 12, 2005; issued August 12 2014.
|
|
26
|
Lichtenberger LM, Wang ZM, Romero JJ,
Ulloa C, Perez JC, Giraud MN and Barreto JC: Non-steroidal
anti-inflammatory drugs (NSAIDs) associate with zwitterionic
phospholipids: Insight into the mechanism and reversal of
NSAID-induced gastrointestinal injury. Nat Med. 1:154–158. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lichtenberger L, Romero JJ and Dial EJ:
Gastrointestinal safety and therapeutic efficacy of parenterally
administered phosphatidylcholine-associated indomethacin in rodent
model systems. Br J Pharmacol. 157:252–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lanza FL, Marathi UK, Anand BS and
Lichtenberger LM: Clinical trial: Comparison of
ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal
safety and analgesic efficacy in osteoarthritic patients. Aliment
Pharmacol Ther. 28:431–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lichtenberger LM, Dial EJ and Fang D: Use
of PC-NSAIDs to protect gingival cells from injury due to cytotoxic
agents. FASEB J. 31:993.9. 2017.
|
|
30
|
Qu Y, Han B, Yu Y, Yao W, Bose S, Karlan
BY, Giuliano AE and Cui X: Evaluation of MCF10A as a reliable model
for normal human mammary epithelial cells. PLoS One.
10:e01312852015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Newbold RF: The significance of telomerase
activation and cellular immortalization in human cancer.
Mutagenesis. 17:539–550. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Howe LR: Inflammation and breast cancer.
Cyclooxygenase/prostaglandin signaling and breast cancer. Breast
Cancer Res. 9:2102007. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chikman B, Vasyanovich S, Lavy R, Habler
L, Tolstov G, Kapiev A, Halevy A and Sandbank J: COX2 expression in
high-grade breast cancer: Evidence for prognostic significance in
the subset of triple-negative breast cancer patients. Med Oncol.
31:9892014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ristimäki A, Sivula A, Lundin J, Lundin M,
Salminen T, Haglund C, Joensuu H and Isola J: Prognostic
significance of elevated cyclooxygenase-2 expression in breast
cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
35
|
Holmes MD, Chen WY, Schnitt SJ, Collins L,
Colditz GA, Hankinson SE and Tamimi RM: COX-2 expression predicts
worse breast cancer prognosis and does not modify the association
with aspirin. Breast Cancer Res Treat. 130:657–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gurpinar E, Grizzle WE and Piazza GA:
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Research.
20:1104–1113. 2014. View Article : Google Scholar
|
|
37
|
Zhou Y, Plowman SJ, Lichtenberger LM and
Hancock JF: The anti-inflammatory drug indomethacin alters
nanoclustering in synthetic and cell plasma membranes. J Biol Chem.
285:35188–35195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Johnson KE, Ceglowski JR, Roweth HG,
Forward JA, Tippy MD, El-Husayni S, Kulenthirarajan R, Malloy MW,
Machlus KR, Chen WY, et al: Aspirin inhibits platelets from
reprogramming breast tumor cells and promoting metastasis. Blood
Adv. 3:198–211. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lichtenberger LM and Vijayan KV: Are
platelets the primary target of aspirin's remarkable anticancer
activity? Cancer Res. 79:3820–3823. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sercombe L, Veerati T, Moheimani F, Wu SY,
Sood AK and Hua S: Advances and challenges of liposome assisted
drug delivery. Front Pharmacol. 6:2862015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Graeser R, Bornmann C, Esser N, Ziroli V,
Jantscheff P, Unger C, Hopt UT, Schaechtele C, Von Dobschuetz E and
Massing U: Antimetastatic effects of liposomal gemcitabine and
empty liposomes in an orthotopic mouse model of pancreatic cancer.
Pancreas. 38:330–337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ichihara H, Zako K, Komizu Y, Goto K and
Ueoka R: Therapeutic effects of hybrid liposomes composed of
phosphatidylcholine and docosahexaenoic acid on the hepatic
metastasis of colon carcinoma along with apoptosis in vivo. Biol
Pharm Bull. 34:901–905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sakakima Y, Hayakawa A, Nagasaka T and
Nakao A: Prevention of hepatocarcinogenesis with
phosphatidylcholine and menaquinone-4: In vitro and in vivo
experiments. J Hepatol. 47:83–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Steiner MR: Localization and
characterization of phospholipase A2 in mouse mammary gland derived
cells. Arch Biochem Biophys. 286:293–299. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rillema JA, Osmialowski EC and Linebaugh
BE: Phospholipase A 2 activity in
9,10-dimethyl-1,2-benzanthracene-induced mammary tumors of rats.
Biochim Biophys Acta. 617:150–155. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lutz J, Augustin AJ, Jäger LJ, Bachmann D
and Brandl M: Acute toxicity and depression of phagocytosis in vivo
by liposomes: Influence of lysophosphatidylcholine. Life Sci.
56:99–106. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chang MC, Lee JJ, Chen YJ, Lin SI, Lin LD,
Jein-Wen Liou E, Huang WL, Chan CP, Huang CC and Jeng JH:
Lysophosphadylcholine induces cytotoxicity/apoptosis and IL-8
production of human endothelial cells: Related mechanisms.
Oncotarget. 8:106177–106189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barenholz Y: Sphingomyelin-lecithin
balance in membranes: Composition, structure and function
relationshipsPhysiology of Membrane Fluidity. 1. Shinitzky M: CRC
Press; Florida: pp. 131–174. 1984
|
|
49
|
Cossins AR and Sinensky M: Adaptation of
membranes to temperature, pressure and exogenous lipidsPhysiology
of Membrane Fluidity. 2. Shinitzky M: CRC Press; Florida: pp. 1–20.
1984
|
|
50
|
Van Blitterswijk WJ: Alterations in lipid
fluidity in the plasma membrane of tumor cellsPhysiology of
Membrane Fluidity. 2. Shinitzky M: CRC Press; Florida: pp. 53–84.
1984
|
|
51
|
Lichtenberger LM, Zhou Y, Jayaraman V,
Doyen JR, O'Neil RG, Dial EJ, Volk DE, Gorenstein DG, Boggara MB
and Krishnamoorti R: Insight into NSAID-induced membrane
alterations, pathogenesis and therapeutics: Characterization of
interaction of NSAIDs with phosphatidylcholine. Biochim Biophys
Acta. 1821:994–1002. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Park JB, Lee CS, Jang JH, Ghim J, Kim YJ,
You S, Hwang D, Suh PG and Ryu SH: Phospholipase signalling
networks in cancer. Nat Rev Cancer. 12:782–792. 2012. View Article : Google Scholar : PubMed/NCBI
|
